Objective. To evaluate efficacy and tolerability of cellex in the treatment of patients with acute disturbance of cerebral blood circulation (ADCBC) used in the clinical practice in the Russian Federation. Material and methods. A trial included 178 patients with ADCBC from 6 Russian clinical centers, 146 (82%) patients were diagnosed with ischemic stroke and 32 (18%) with hemorrhagic stroke in the age of 35-80 years. Results. One hundred and sixty-six patients have completed the trial. The better outcome with the decrease of motor, visual, speech and sensory disorders was found after 4-week treatment. Conclusion. Cellex may be recommended for treatment in acute and early rehabilitation stages of ADCBC.